Sign in Sign up for free

Cellectis Ret. on assets

What is the Ret. on assets of Cellectis?

The Ret. on assets of Cellectis is -23.15%

What is the definition of Ret. on assets?



Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.

ttm (trailing twelve months)

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Ret. on assets of companies in the Health Care sector on NASDAQ compared to Cellectis

What does Cellectis do?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Companies with ret. on assets similar to Cellectis